366 related articles for article (PubMed ID: 1359153)
1. Effect of P-glycoprotein expression on sensitivity to hormones in MCF-7 human breast cancer cells.
Clarke R; Currier S; Kaplan O; Lovelace E; Boulay V; Gottesman MM; Dickson RB
J Natl Cancer Inst; 1992 Oct; 84(19):1506-12. PubMed ID: 1359153
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
3. Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen.
Herman ME; Katzenellenbogen BS
J Steroid Biochem Mol Biol; 1996 Oct; 59(2):121-34. PubMed ID: 9010327
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
5. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
6. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo.
Vickers PJ; Dickson RB; Shoemaker R; Cowan KH
Mol Endocrinol; 1988 Oct; 2(10):886-92. PubMed ID: 3185565
[TBL] [Abstract][Full Text] [Related]
7. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
8. Expression of human estrogen receptor using an efficient adenoviral gene delivery system is able to restore hormone-dependent features to estrogen receptor-negative breast carcinoma cells.
Lazennec G; Katzenellenbogen BS
Mol Cell Endocrinol; 1999 Mar; 149(1-2):93-105. PubMed ID: 10375022
[TBL] [Abstract][Full Text] [Related]
9. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines.
Néri C; Berthois Y; Schatz B; Drieu K; Martin PM
Breast Cancer Res Treat; 1990 Feb; 15(2):85-93. PubMed ID: 2138918
[TBL] [Abstract][Full Text] [Related]
10. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations.
van Agthoven T; van Agthoven TL; Dekker A; Foekens JA; Dorssers LC
Mol Endocrinol; 1994 Nov; 8(11):1474-83. PubMed ID: 7533260
[TBL] [Abstract][Full Text] [Related]
11. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
Zyad A; Bénard J; Tursz T; Clarke R; Chouaib S
Cancer Res; 1994 Feb; 54(3):825-31. PubMed ID: 7905787
[TBL] [Abstract][Full Text] [Related]
12. Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines.
Sommer A; Hoffmann J; Lichtner RB; Schneider MR; Parczyk K
J Steroid Biochem Mol Biol; 2003 May; 85(1):33-47. PubMed ID: 12798355
[TBL] [Abstract][Full Text] [Related]
13. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
Brünner N; Frandsen TL; Holst-Hansen C; Bei M; Thompson EW; Wakeling AE; Lippman ME; Clarke R
Cancer Res; 1993 Jul; 53(14):3229-32. PubMed ID: 8324732
[TBL] [Abstract][Full Text] [Related]
14. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity.
Dumont JA; Bitonti AJ; Wallace CD; Baumann RJ; Cashman EA; Cross-Doersen DE
Cell Growth Differ; 1996 Mar; 7(3):351-9. PubMed ID: 8838865
[TBL] [Abstract][Full Text] [Related]
15. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells.
Weaver CA; Springer PA; Katzenellenbogen BS
Mol Endocrinol; 1988 Oct; 2(10):936-45. PubMed ID: 2460749
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in the evolution of progestin resistance in human breast cancer cells.
Murphy LC; Dotzlaw H; Wong MS; Miller T; Murphy LJ
Cancer Res; 1991 Apr; 51(8):2051-7. PubMed ID: 1849041
[TBL] [Abstract][Full Text] [Related]
17. Identification of a distinctive P-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated X-irradiation.
Hill BT; Whelan RD; Hurst HC; McClean S
Cancer; 1994 Jun; 73(12):2990-9. PubMed ID: 7911070
[TBL] [Abstract][Full Text] [Related]
18. Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.
de Cremoux P; Tran-Perennou C; Brockdorff BL; Boudou E; Brünner N; Magdelénat H; Lykkesfeldt AE
Endocr Relat Cancer; 2003 Sep; 10(3):409-18. PubMed ID: 14503918
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2.
Imai Y; Ishikawa E; Asada S; Sugimoto Y
Cancer Res; 2005 Jan; 65(2):596-604. PubMed ID: 15695404
[TBL] [Abstract][Full Text] [Related]
20. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]